Biogen Inc.

FDA approval of a subcutaneous starter dose for Leqembi and ongoing Alzheimer's drug development signal meaningful pipeline progress. Analyst sentiment remains predominantly positive, with 62.5% buy ratings and a consensus price target of $230.18, reflecting confidence in Biogen's neurology franchise delivering long-term value.

The mid-stage diranersen trial missed its primary endpoint, with the drug's lowest dose inexplicably outperforming higher doses. This data failure rattled investors, sending the stock down 8%, and raises serious doubts about the reliability of Biogen's Alzheimer's pipeline as a future revenue driver.

A broad consensus of 22 out of 31 analysts rate Biogen a Buy, with an average 12-month price target of $225.45 and a high estimate of $300. Firms such as RBC Capital, Needham, and Truist Securities have recently maintained or upgraded their positions, signaling strong institutional conviction in upside potential.

Despite the buy consensus, significant disagreement persists, with price targets ranging widely from $157 to $300 and 13 analysts recommending a Hold. Wedbush reaffirmed a neutral rating with a $201 target, and Mizuho cut its target from $236 to $221, reflecting uncertainty over Biogen's near-term earnings trajectory.

Biogen posted a strong earnings beat in April, reporting $3.57 EPS versus a $2.95 consensus estimate, and set FY 2026 guidance at $14.25–$15.25 EPS. Analysts at Cantor Fitzgerald and Jefferies reiterated overweight and buy ratings, suggesting confidence in Biogen's operational execution and cash flow generation of $1.28 billion.

Despite the earnings beat, analysts forecast only $13.6 EPS for the current fiscal year — below Biogen's own guidance midpoint — highlighting skepticism about sustainability. Clinical trial setbacks and competitive pressures in neurology remain key risks, with the stock's technical signals mixed and a sell signal recently triggered from a pivot top.